



Retrospective Study

Analysis of textbook outcomes for ampullary carcinoma patients following pancreaticoduodenectomy

Xiao-Jie Zhang, He Fei, Chun-Guang Guo, Chong-Yuan Sun, Ze-Feng Li, Zheng Li, Ying-Tai Chen, Xu Che, Dong-Bing Zhao

Specialty type: Gastroenterology and hepatology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B, B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Kitamura K, Japan; Shah OJ, India; Varma V, India

Received: July 11, 2023

Peer-review started: July 11, 2023

First decision: August 31, 2023

Revised: September 1, 2023

Accepted: September 7, 2023

Article in press: September 7, 2023

Published online: October 27, 2023



Xiao-Jie Zhang, He Fei, Chun-Guang Guo, Chong-Yuan Sun, Ze-Feng Li, Zheng Li, Ying-Tai Chen, Xu Che, Dong-Bing Zhao, Department of Pancreatic and Gastric Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

Xu Che, Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China

Corresponding author: Dong-Bing Zhao, MD, Doctor, Department of Pancreatic and Gastric Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China.

dbzhao@cicams.ac.cn

Abstract

BACKGROUND

Textbook outcomes (TOs) have been used to assess the quality of surgical treatment for many digestive tumours but not ampullary carcinoma (AC).

AIM

To discuss the factors associated with achieving a TO and further explore the prognostic value of a TO for AC patients undergoing curative pancreaticoduodenectomy (PD).

METHODS

Patients who underwent PD at the China National Cancer Center between 1998 and 2020 were identified. A TO was defined by R0 resection, examination of ≥ 12 Lymph nodes, no prolonged hospitalization, no intensive care unit treatment, no postoperative complications, and no 30-day readmission or mortality. Cox regression analysis was used to identify the prognostic value of a TO for overall survival (OS) and recurrence-free survival (RFS). Logistic regression was used to identify predictors of a TO. The rate of a TO and of each indicator were compared in patients who underwent surgery before and after 2010.

RESULTS

Ultimately, only 24.3% of 272 AC patients achieved a TO. A TO was indepen-

dently associated with improved OS [hazard ratio (HR): 0.443, 95% confidence interval (95%CI): 0.276-0.711, $P = 0.001$] and RFS (HR: 0.379, 95%CI: 0.228-0.629, $P < 0.001$) in the Cox regression analysis. Factors independently associated with a TO included a year of surgery between 2010 and 2020 (OR: 4.549, 95%CI: 2.064-10.028, $P < 0.001$) and N1 stage disease (OR: 2.251, 95%CI: 1.023-4.954, $P = 0.044$). In addition, the TO rate was significantly higher in patients who underwent surgery after 2010 ($P < 0.001$) than in those who underwent surgery before 2010.

CONCLUSION

Only approximately a quarter (24.3%) of AC patients achieved a TO following PD. A TO was independently related to favourable oncological outcomes in AC and should be considered as an outcome measure for the quality of surgery. Further multicentre research is warranted to better elucidate its impact.

Key Words: Ampullary carcinoma; Textbook outcomes; Pancreaticoduodenectomy; Prognosis

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Surgery has improved substantially with advances in surgical techniques, however we still lack an effective measure to evaluate the quality of surgery in ampullary carcinoma. As a composite metric, textbook outcome (TO) concluded the strengths of all indicators based on important short-term outcomes, which was more reliable and comprehensive than single outcome measure. Pancreaticoduodenectomy was still quite complicated and required a broad judgement to monitor and compare the quality of procedures. TO should be considered as an outcome measurement for the quality of surgery, our study will be helpful in completely and effectively evaluating the overall quality of surgical care, and even in the hospital administration.

Citation: Zhang XJ, Fei H, Guo CG, Sun CY, Li ZF, Li Z, Chen YT, Che X, Zhao DB. Analysis of textbook outcomes for ampullary carcinoma patients following pancreaticoduodenectomy. *World J Gastrointest Surg* 2023; 15(10): 2259-2271

URL: <https://www.wjgnet.com/1948-9366/full/v15/i10/2259.htm>

DOI: <https://dx.doi.org/10.4240/wjgs.v15.i10.2259>

INTRODUCTION

Ampullary carcinoma (AC) is a rare tumour constituting only 0.6%–0.8% of all digestive system malignancies[1], and the incidence of AC has increased over the last 2 decades[2]. Pancreaticoduodenectomy (PD) is one of the standard treatment strategies for curative purposes. The prognosis of AC patients is better than that of patients with other peri ACs[3], with a nearly 50% resection rate[4]. Surgery has improved substantially with advances in surgical techniques; however, there is still a lack an effective measure to evaluate the quality of surgery. Sun *et al*[5] found inflammatory index can be regarded as a more useful prognostic index and Gonzalez *et al*[3] established a nomogram to predict disease-specific survival; however, these method did not have intuitive indicators. Recently, textbook outcomes (TOs) have emerged and been applied in evaluating treatments for many tumours. To our knowledge, no previous study has explored the clinical value of a TO in AC patients.

The concept of the TO was first proposed by Kolfschoten *et al*[6] to investigate hospital variation in the Netherlands as a composite quality metric that encompassed several indicators of quality. Generally, individual quality metrics such as mortality and complications are applied to evaluate the quality of surgery[7,8]; however, these single indicators may lack practicality in reflecting the overall prognosis. As a composite metric, the TO represents the strength of all indicators based on important short-term outcomes and is thus more reliable and comprehensive than a single outcome measure[9, 10]. Since the concept of the TO emerged in surgery for colon cancer, it has been defined for the treatment of many other tumours, such as gastroesophageal cancer and intrahepatic cholangiocarcinoma[9,11]. The definition of a TO follows the all-or-none principle[12] because partially favourable outcomes are not perfect postoperative outcomes.

Previous studies have successfully proven that a TO is associated with improved long-term survival in pancreatic adenocarcinoma patients who undergo PD[13-15], as well as for patients in other surgical fields[6,16,17]. Milbank considered PD to require a broad judgement to monitor and compare the quality of procedures[18]. Based on the above situation, the aims of this study were to propose a TO definition for AC patients and characterize the impact of a TO on survival. In addition, we assessed the factors associated with achieving a TO.

MATERIALS AND METHODS

Data source and study population

Patients who underwent surgery for AC between 1998 and 2020 in the China National Cancer Center were selected for analysis. Inclusion criteria: (1) Pathologically proved as AC; and (2) Patients were submitted to radical surgery. Patients

with missing data necessary to define TO were excluded: R0 resection ($n = 4$), lymph nodes examined ($n = 9$), hospitalization ($n = 8$) intensive care unit (ICU) treatment ($n = 6$), postoperative complications ($n = 10$), tumor differentiation ($n = 4$). A total of 41 patients were excluded from analysis and 272 AC patients were included.

TO

TO represents optimal oncologic care after PD for AC as a single composite measure. TO was achieved if the following indicators are fulfilled: The surgical margin was negative (R0 resection), ≥ 12 Lymph nodes examined (American Joint Committee on Cancer, eighth edition)[19], no prolonged hospitalization ($< 75^{\text{th}}$ percentile)[6,20], no ICU treatment, no postoperative complications, no 30-day readmission or mortality[13], hospitalization was defined as day of operation to day of discharge.

Statistical analysis

we counted the number of patients each of the indicator and calculated the cumulative proportion. The collected data was presented as frequencies and proportions, and was compared between the groups with and without TO using the Chi-square test. Cox regression analysis was used to identify if TO was an independent prognostic factor for overall survival (OS) and recurrence-free survival (RFS). Multivariable logistic regression was performed to determine the relationship between baseline characteristics and TO, factors with $P < 0.2$ in univariate analysis were included in the multivariate analysis, and odds ratios (OR) or hazard ratios (HR) and their 95% confidence intervals (95%CI) were reported. Survival curves of OS and RFS were plotted using the Kaplan–Meier method to determine the effect of TO on survival. We divided the patients into two groups by the year of surgery before and after 2010 to see the TO rate trend.

Follow-up was mainly conducted by telephone and though outpatient rechecks, other information was obtained by medical records and population death register information system. All data were analyzed with SPSS software (version 21; SPSS Inc., Chicago, IL, United States). Kaplan–Meier survival analyses were performed in R software (Version 3.5.1; R Foundation for Statistical Computing, Vienna, Austria). P value < 0.05 was considered statistically significant.

RESULTS

TO and survival

A total of 272 AC patients met the inclusion criteria. A TO was observed in 66 (24.3%) patients. Among the indicators used to define a TO, R0 resection (99.6%), no 30-day readmission or mortality (93.0%) and no ICU treatment (90.1%) were achieved easily, while Examination of ≥ 12 Lymph nodes (58.5%) and no postoperative complications (48.9%) were not achieved as easily. The data for the 6 TO indicators and the cumulative proportions are shown in Figure 1.




Figure 1 Textbook Outcome percentages (parameter and cumulative) after pancreatoduodenectomy.

Cohort characteristics

Patients were divided into a TO group (66 patients, 24.3%) and a non-TO group (206 patients, 75.7%). There were significant differences in the year of surgery, N stage, TNM stage and lymphovascular invasion ($P < 0.05$) between the two groups and no significant differences in sex, age, operation time, blood transfusion, tumour size, differentiation, CA199, T stage or adjuvant treatment ($P > 0.05$). Baseline characteristics for the TO and non-TO groups are presented in Table 1.


Table 1 Baseline characteristics for patients with or without a Textbook Outcome after pancreatoduodenectomy

Characteristic	Textbook outcome		No textbook outcome		P value
	n = 66	Percentage	n = 206	Percentage	
Year of surgery					< 0.001
1998-2010	15	22.7%	117	56.8%	
2011-2020	51	77.3%	89	43.2%	
Sex					0.634
Male	40	60.6%	118	57.3%	
Female	26	39.4%	88	42.7%	
Age (yr)					0.618
≤ 60	42	63.6%	124	60.2%	
> 60	24	36.4%	82	39.8%	
Operation time (h)					0.622
≤ 6	45	68.2%	147	71.4%	
> 6	21	31.8%	59	28.3%	
Blood transfusion					0.328
No	35	53.0%	95	46.1%	
Yes	31	47.0%	111	53.9%	
Tumor size (cm)					0.155
≤ 2.0	27	40.9%	105	51.0%	
> 2.0	39	59.1%	101	49.0%	
Differentiation					0.369
Well	10	15.2%	47	22.8%	
Moderate	29	43.9%	88	42.7%	
Poor	27	40.9%	71	34.5%	
CA199					0.941
0-40	23	34.8%	74	35.9%	
> 40	37	56.1%	111	53.9%	
unknown	6	9.1%	21	10.2%	
N stage					0.038
N0	39	59.1%	154	74.8%	
N1	23	34.8%	41	19.9%	
N2	4	6.1%	11	5.3%	
T stage					0.585
T1	9	13.6%	33	16.0%	
T2	26	39.4%	67	32.5%	
T3	31	47.0%	106	51.5%	
TNM stage					0.034
I	29	43.9%	93	45.1%	
II	10	15.2%	58	28.2%	
III	27	40.9%	55	26.7%	
Lymphovascular invasion					0.001
No	40	60.6%	166	80.6%	

Yes	26	39.4%	40	19.4%
Adjuvant treatment				0.223
No	15	22.7%	31	15.0%
Yes	16	24.2%	43	20.9%
Unknown	35	53%	132	64.1%

Survival analysis

On Kaplan-Meier survival analysis, a TO was associated with better OS and RFS (all $P < 0.05$) in AC (Figure 2). The median survival and median recurrence-free survival in the non-TO group were 48 and 42 mo, respectively, whereas the median survival was not reached in the TO group. The Kaplan-Meier survival curve is shown in Figure 2.



DOI: 10.4240/wjgs.v15.i10.2259 Copyright ©The Author(s) 2023.

Figure 2 The Kaplan-Meier survival curves stratified by achievement of textbook outcome for ampullary carcinoma patients after pancreaticoduodenectomy. A: Overall survival curve; B: Recurrence free survival curve. ICU: Intensive care unit; OS: Overall survival; RFS: Recurrence free survival; TO: Textbook outcomes.

Cox regression analysis showed that a TO was related to improved OS (HR: 0.443, 95%CI: 0.276-0.711, $P = 0.001$) and RFS (HR: 0.379, 95%CI: 0.228-0.629, $P < 0.001$) and that N1 stage disease (HR: 1.872, 95%CI: 1.178-2.977, $P = 0.008$) was an independent risk factor for OS. Regarding RFS, preoperative CA 199 Level > 40 (HR: 1.601, 95%CI: 1.025-2.501, $P = 0.038$), N1 stage disease (HR: 1.675, 95%CI: 1.006-2.789, $P = 0.047$) and lymphovascular invasion (HR: 1.892, 95%CI: 1.161-3.081, $P = 0.010$) were all independent risk factors. The detailed data are depicted in Tables 2 and 3.

TO-associated factors

Logistic regression revealed that a year of surgery between 2010 and 2020 (OR: 4.549, 95%CI: 2.064-10.028, $P < 0.001$) and N1 stage disease (HR: 2.251, 95%CI: 1.023-4.954, $P = 0.044$) were independently associated with lower odds of a TO. The results of the univariable and multivariable logistic regression analyses are shown in Table 4.

Time-related trends

Fifteen (132, 11.4%) patients treated before 2010 and 52 (140, 36.4%) patients treated after 2010 achieved a TO. The TO rate significantly increased after 2010 ($P < 0.001$), mainly due to improvements in lymphadenectomy ($P < 0.001$) and 30-day readmission or mortality ($P = 0.030$). The detailed data are depicted in Table 5.

DISCUSSION

TOs are composite measures that represent ideal outcomes and have been used to assess the quality of surgical treatment for many digestive tumours. To our knowledge, this is the first study to define and examine a TO in the evaluation of

Table 2 Univariable and multivariable Cox regression analyses of clinicopathological factors for overall survival

Characteristic	Univariable analysis		Multivariable analysis	
	HR (95%CI)	P value	HR (95%CI)	P value
Textbook outcome				
No	Reference		Reference	
Yes	0.598 (0.383-0.934)	0.024	0.443 (0.276-0.711)	0.001
Year of surgery				
1998-2010	Reference			
2011-2020	1.095 (0.767-1.562)	0.619		
Sex				
Male	Reference			
Female	0.914 (0.641-1.303)	0.619		
Age (yr)				
≤ 60	Reference			
> 60	1.254 (0.875-1.797)	0.218		
Operation time (h)				
≤ 6	Reference			
> 6	1.259 (0.861-1.839)	0.235		
Blood transfusion				
No	Reference			
yes	0.998 (0.702-1.417)	0.990		
Tumor size (cm)				
≤ 2.0	Reference		Reference	
> 2.0	1.396 (0.985-1.978)	0.061	1.327 (0.919-1.917)	0.131
Differentiation				
Poor	Reference		Reference	
Moderate	1.077 (0.730-1.588)	0.709	1.243 (0.830-1.863)	0.291
Well	0.644 (0.389-1.065)	0.086	1.026 (0.563-1.868)	0.934
CA199				
0-40	Reference		Reference	
> 40	1.495 (1.010-2.213)	0.045	1.339 (0.885-2.026)	0.168
Unknown	1.393 (0.741-2.619)	0.303	2.022 (1.025-3.990)	0.042
N stage				
N0	Reference		Reference	
N1	1.939 (1.303-2.886)	0.001	1.872 (1.178-2.977)	0.008
N2	2.077 (1.002-4.305)	0.049	1.850 (0.856-4.002)	0.118
T stage				
T1	Reference		Reference	
T2	1.092 (0.616-1.936)	0.764	0.824 (0.441-1.542)	0.546
T3	2.230 (1.309-3.799)	0.003	1.469 (0.771-2.799)	0.243
Lymphovascular invasion				
No	Reference		Reference	
Yes	1.528 (1.026-2.275)	0.037	1.252 (0.797-1.966)	0.330

Adjuvant treatment		
No	Reference	
Yes	1.082 (0.624-1.876)	0.780
Unknown	0.886 (0.548-1.431)	0.620

95%CI: 95% Confidence interval; HR: Hazard ratio.

Table 3 Univariable and multivariable Cox regression analyses of clinicopathological factors for recurrence free survival

Characteristic	Univariable analysis		Multivariable analysis	
	HR (95%CI)	P value	HR (95%CI)	P value
Textbook outcome				
No	Reference		Reference	
Yes	0.607 (0.382-0.963)	0.034	0.379 (0.228-0.629)	< 0.001
Year of surgery				
1998-2010	Reference			
2011-2020	1.030 (0.703-1.509)	0.879		
Sex				
Male	Reference			
Female	1.009 (0.685-1.485)	0.965		
Age (yr)				
≤ 60	Reference			
> 60	0.972 (0.652-1.449)	0.891		
Operation time (h)				
≤ 6	Reference			
> 6	1.051 (0.689-1.603)	0.818		
Blood transfusion				
No	Reference			
Yes	0.932 (0.638-1.363)	0.717		
Tumor size (cm)				
≤ 2.0	Reference		Reference	
> 2.0	1.540 (1.051-2.257)	0.027	1.365 (0.909-2.048)	0.133
Differentiation				
Poor	Reference		Reference	
Moderate	1.112 (0.730-1.693)	0.622	1.472 (0.946-2.290)	0.086
Well	0.546 (0.307-0.974)	0.040	1.002 (0.508-1.976)	0.997
CA199				
0-40	Reference			
> 40	1.751 (1.145-2.677)	0.010	1.601 (1.025-2.501)	0.038
Unknown	1.225 (0.584-2.568)	0.591	1.646 (0.746-3.634)	0.217
N stage				
N0	Reference		Reference	
N1	1.801 (1.170-2.771)	0.008	1.675 (1.006-2.789)	0.047
N2	2.563 (1.173-5.604)	0.018	1.807 (0.833-4.138)	0.162

T stage				
T1	Reference		Reference	
T2	1.152 (0.613-2.166)	0.661	0.885 (0.446-1.754)	0.726
T3	2.488 (1.387-4.463)	0.002	1.419 (0.709-2.842)	0.323
Lymphovascular invasion				
No	Reference		Reference	
Yes	2.002 (1.321-3.033)	0.001	1.892 (1.161-3.081)	0.010
Adjuvant treatment				
No	Reference			
Yes	1.271 (0.730-2.215)	0.397		
Unknown	0.671 (0.405-1.112)	0.122		

95%CI: 95% Confidence interval; HR: Hazard ratio.

outcomes in AC patients undergoing PD. We performed a hospital-based retrospective study of 272 patients undergoing curative surgery and found that only 24.3% achieved a TO. In addition, we found that a TO was independently associated with improved OS and RFS. The current study is important because it is the first to demonstrate that a TO is a potentially significant composite indicator for evaluating the quality of surgical treatment for AC.

Improving the quality of care remains a topic of interest for patients and physicians. As far back as 20 years ago, the Society for Thoracic Surgeons started a clinical audit to monitor their results[21]. Recently, TOs have become increasingly accessible for use in assessing the quality of surgical care as combinations of universal variables[17]. Prior studies have typically used isolated parameters to measure quality, such as prolonged hospitalization, morbidity, mortality and readmission[7,22,23]. However, the limitations of these individual metrics were gradually revealed with the progression of research, and they cannot reflect the quality of care completely[14,24,25]. On the other hand, hospitals might perform well in terms of one indicator and worse in terms of another[6,7]. Combining these isolated parameters to build a multidimensional metric might be a more accurate method for measuring quality[26]. As such, TOs are more reliable and comprehensive than single outcome measures, and the use of TOs might address different domains of surgical quality[27-29]. Of note, the all-or-none principle[12] could more accurately reflect desirable patient outcomes and align with ideal patient experiences. From this perspective, a TO is a much more patient-centred metric.

A TO directly reflects the short-term outcomes of rapid recovery and early discharge. However, assessment of long-term outcomes is equally important. Several studies have examined the relationship between a TO and survival among cancer patients. Kulshrestha *et al*[30] found that 37.2% of oesophageal cancer patients achieved a TO, which appeared to be associated with improved OS [Ed1]. Aquina *et al*[31] indicated that achieving a TO was related to better OS in the treatment of all eight kinds of cancer in the National Cancer Database. Consistently, similar results were found for PD in the treatment of pancreatic neuroendocrine tumours[32] and pancreatic adenocarcinoma[13-15,33]. Furthermore, we found that achieving a TO was independently associated with improved OS (HR: 0.443, 95%CI: 0.276-0.711, $P = 0.001$) and RFS (HR: 0.379, 95%CI: 0.228-0.629, $P < 0.001$). As such, achieving a TO is very significant, and these studies demonstrate the necessity and importance of improving surgical techniques and the quality of clinical care[34,35]. To this end, a TO is a reliable and valuable metric and should be applied in more clinical research.

Only approximately a quarter (24.3%) of patients achieved a TO in our research, meaning that adverse events occurred in a sizable fraction of patients. Previous studies on the achievement of a TO have shown large variations, with an average of 49% in colon cancer[6], 25.5% in intrahepatic cholangiocarcinoma[8], 32.1% in gastric cancer and 29.7% in oesophageal cancer patients[15]. Merath *et al*[36] found that TO rates varied from 11.1% to 69.6% after pancreatic surgery among hospitals. Aquina and associates[31] showed that the TO rate of pancreatic cancer patients was the lowest at 25% among that of all cancer patients. Similarly, only 16.8% of patients achieved a TO in the study by Sweigert and his colleagues[13]. In the present study, the achievement of a TO was mainly hampered by examination of ≥ 12 Lymph nodes (58.5%) and no postoperative complications (48.9%). The major hampering indicators in other studies include R0 resection[31], no prolonged hospital stay[36], and receipt of adjuvant chemotherapy within 12 wk[13,15], which showed considerable variation. As mentioned above, the wide variation among different hospitals further supports the superiority of TOs. Factors independently associated with a TO included a year of surgery between 2010 and 2020 (OR: 4.549, 95%CI: 2.064-10.028, $P < 0.001$) and N1 stage disease (OR: 2.251, 95%CI: 1.023-4.954, $P = 0.044$). Similar results were also found in pancreatic adenocarcinoma patients[13], which was mainly attributed to advancements in surgical techniques and the increasing number of examined lymph nodes. The proportion of AC patients with a TO remained low even at a large medical centre such as ours, which indicates great potential for improvement. Overall, a TO could be applied to guide quality improvement as a reliable metric[31].

Due to the observation of increasing trends in TO rates over the years ($P < 0.05$), we divided the patients into two groups by the year of surgery before and after 2010 and compared the trends of every indicator over time. Of note, the improvement in the TO rate was mainly attributed to the reduction in postoperative complications and increase in adequate lymphadenectomy, which indicated that there were significant advances in surgical techniques over time.

Table 4 Univariable and multivariable logistic regression analyses of factors associated with textbook outcome

Characteristic	Univariable analysis		Multivariable analysis	
	OR (95%CI)	P value	OR (95%CI)	P value
Year of surgery				
1998-2010	Reference		Reference	
2011-2020	4.470 (2.361-8.462)	< 0.001	4.549 (2.064-10.028)	< 0.001
Sex				
Male	Reference			
Female	0.872 (0.495-1.535)	0.634		
Age (yr)				
≤ 60	Reference			
> 60	0.864 (0.487-1.534)	0.618		
Operation time (h)				
≤ 6	Reference			
> 6	1.163 (0.638-2.118)	0.622		
Transfusion				
No	Reference			
Yes	0.758 (0.435-1.321)	0.328		
Tumor size (cm)				
≤ 2.0	Reference		Reference	
> 2.0	1.502 (0.856-2.633)	0.156	1.728 (0.924-3.231)	0.087
Differentiation				
Poor	Reference		Reference	
Moderate	0.867 (0.471-1.595)	0.646	1.194 (0.597-2.390)	0.616
Well	0.559 (0.248-1.262)	0.162	1.007 (0.360-2.812)	0.990
CA199				
0-40	Reference			
> 40	1.072 (0.590-1.950)	0.819		
Unknown	0.919 (0.331-2.551)	0.872		
N stage				
N0	Reference		Reference	
N1	2.215 (1.192-4.117)	0.012	2.251 (1.023-4.954)	0.044
N2	1.436 (0.434-4.754)	0.554	1.236 (0.314-4.864)	0.762
T stage				
T1	Reference		Reference	
T2	1.423 (0.599-3.380)	0.424	1.205 (0.455-3.191)	0.707
T3	1.072 (0.464-2.481)	0.870	0.449 (0.150-1.341)	0.151
Lymphovascular invasion				
No	Reference		Reference	
Yes	2.697 (1.477-4.927)	0.001	1.483 (0.688-3.199)	0.315
Adjuvant treatment				
No	Reference		Reference	
Yes	0.769 (0.331-1.785)	0.541	1.144 (0.450-2.912)	0.777

Unknown	0.548 (0.267-1.126)	0.102	1.459 (0.629-3.387)	0.379
---------	---------------------	-------	---------------------	-------

95%CI: 95% Confidence interval; OR: Odds ratio.

Table 5 Trends over years for individual textbook outcome parameters after controlling clinicopathological factors by logistic regression analyses

Characteristic	OR (95%CI)	P value
R0 resection	-	-
≥ 12 lymph nodes examined	14.620 (5.323-40.156)	< 0.001
No ICU treatment	0.255 (0.052-1.258)	0.093
No postoperative complications	3.375 (1.268-8.984)	0.015
No prolonged hospitalization	2.057 (0.738-5.734)	0.168
No 30-d readmission or mortality	6.399 (0.496-82.620)	0.155

95%CI: 95% Confidence interval; ICU: Intensive care unit; OR: Odds ratio.

However, Hyer *et al*[37] found that the improvement was mainly driven by a decline in mortality and prolonged hospital stay. Perioperative management should be further strengthened to better improve the quality of surgery.

There are several limitations to this study. First, the current study was a retrospective review of data from a large single centre, which might introduce the risk of selection bias. Second, our study had some missing data, such as estimated blood loss and details regarding adjuvant treatment. In addition, only a few patients underwent minimally invasive surgery, a subgroup analysis was not conducted. These factors could limit the generalizability of the study results. Third, no patients with T4 stage disease were included in this study due to the combined effects of the inclusion and exclusion criteria; therefore, the TO rate is possibly lower than described. Fourth, the TO definition was based on previous studies and is still in the early phase of development. Some indicators, such as patient satisfaction, social vulnerability[38] and hospital volume[39], which have been shown to affect the chances of achieving a TO, were not evaluated. There is an urgent need for a standard definition for a TO in AC patients who undergo PD.

CONCLUSION

In conclusion, only approximately a quarter (24.3%) of patients achieved TO in AC patients following PD and achieving TO was independently related to favorable oncological outcomes in AC. This study demonstrated that TO was a simple and reliable composite measure of ideal outcomes following PD which could completely and effectively evaluate the overall quality of surgical care. Further multicenter research is warranted to better elucidate its impact.

ARTICLE HIGHLIGHTS

Research background

Textbook outcome (TO) is a composite measure that represents the ideal outcome and has been used to assess the quality of surgical treatment in many digestive tumors.

Research motivation

Lack of an effective measure to evaluate the quality of surgery for ampullary carcinoma (AC).

Research objectives

This study aimed to investigate the impact of TO on survival for AC patients following pancreaticoduodenectomy and the factors associated with achieving TO.

Research methods

We defined the concept of TO in ampullary carcinoma and cox regression analysis was used to identify if TO was an independent prognostic factor for overall survival and recurrence free survival.

Research results

Only approximately a quarter (24.3%) of patients achieved TO and TO was independently related to favorable oncological outcomes in AC.

Research conclusions

TO was a simple and reliable composite measure of ideal outcomes following pancreaticoduodenectomy.

Research perspectives

Further multicenter research is warranted to better elucidate the impact of TO.

FOOTNOTES

Author contributions: Zhang XJ, Fei H and Guo CG contributed equally to this work; Chen YT, Che X and Zhao DB designed the research study, they are the corresponding authors of this paper; Fei H and Zhang XJ analyzed the data; Sun CY, Li Z and Li ZF collected the data; All author wrote the manuscript; All authors have read and approve the final manuscript.

Institutional review board statement: Ethical review and approval were not required for this study in accordance with the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College.

Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous data that were obtained after each patient agreed to treatment by written consent.

Conflict-of-interest statement: None of the authors have conflicts of interest related to the manuscript.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Xiao-Jie Zhang 0000-0001-9850-9806; He Fei 0000-0003-4831-4028; Chun-Guang Guo 0000-0002-2674-6586; Chong-Yuan Sun 0000-0003-1354-2063; Ze-Feng Li 0000-0002-5345-3527; Zheng Li 0000-0003-4415-6552; Ying-Tai Chen 0000-0003-4980-6315; Xu Che 0000-0002-1634-4524; Dong-Bing Zhao 0000-0002-6770-2694.

S-Editor: Lin C

L-Editor: A

P-Editor: Yu HG

REFERENCES

- 1 Vanbiervliet G, Strijker M, Arvanitakis M, Aelvoet A, Arnelo U, Beyna T, Busch O, Deprez PH, Kunovsky L, Larghi A, Manes G, Moss A, Napoleon B, Nayar M, Pérez-Cuadrado-Robles E, Seewald S, Barthet M, van Hooft JE. Endoscopic management of ampullary tumors: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy* 2021; **53**: 429-448 [PMID: 33728632 DOI: 10.1055/a-1397-3198]
- 2 de Jong EJM, Geurts SME, van der Geest LG, Besselink MG, Bouwense SAW, Buijsen J, Dejong CHC, Heij LR, Koerkamp BG, de Hingh IHJ, Hoge C, Kazemier G, van Laarhoven HWM, de Meijer VE, Mohammad NH, Strijker M, Timmermans KCAA, Valkenburg-van Iersel LBJ, Wilmink JW, Tjan-Heijnen VCG, de Vos-Geelen J; Dutch Pancreatic Cancer Group (DPCG). A population-based study on incidence, treatment, and survival in ampullary cancer in the Netherlands. *Eur J Surg Oncol* 2021; **47**: 1742-1749 [PMID: 33712346 DOI: 10.1016/j.ejso.2021.02.028]
- 3 Gonzalez RS, Bagci P, Basturk O, Reid MD, Balci S, Knight JH, Kong SY, Memis B, Jang KT, Ohike N, Tajiri T, Bandyopadhyay S, Krasinskas AM, Kim GE, Cheng JD, Adsay NV. Intrapaneatic distal common bile duct carcinoma: Analysis, staging considerations, and comparison with pancreatic ductal and ampullary adenocarcinomas. *Mod Pathol* 2016; **29**: 1358-1369 [PMID: 27469329 DOI: 10.1038/modpathol.2016.125]
- 4 Rostain F, Hamza S, Drouillard A, Faivre J, Bouvier AM, Lepage C. Trends in incidence and management of cancer of the ampulla of Vater. *World J Gastroenterol* 2014; **20**: 10144-10150 [PMID: 25110442 DOI: 10.3748/wjg.v20.i29.10144]
- 5 Sun S, He C, Wang J, Huang X, Wu J, Li S. The prognostic significance of inflammation-based scores in patients with ampullary carcinoma after pancreaticoduodenectomy. *BMC Cancer* 2020; **20**: 981 [PMID: 33036573 DOI: 10.1186/s12885-020-07482-0]
- 6 Kolfsochten NE, Kievit J, Gooiker GA, van Leersum NJ, Snijders HS, Eddes EH, Tollenaar RA, Wouters MW, Marang-van de Mheen PJ. Focusing on desired outcomes of care after colon cancer resections; hospital variations in 'textbook outcome'. *Eur J Surg Oncol* 2013; **39**: 156-163 [PMID: 23102705 DOI: 10.1016/j.ejso.2012.10.007]

- 7 Parina RP, Chang DC, Rose JA, Talamini MA. Is a low readmission rate indicative of a good hospital? *J Am Coll Surg* 2015; **220**: 169-176 [PMID: 25529903 DOI: 10.1016/j.jamcollsurg.2014.10.020]
- 8 Kneuert PJ, Pitt HA, Bilimoria KY, Smiley JP, Cohen ME, Ko CY, Pawlik TM. Risk of morbidity and mortality following hepato-pancreato-biliary surgery. *J Gastrointest Surg* 2012; **16**: 1727-1735 [PMID: 22760965 DOI: 10.1007/s11605-012-1938-y]
- 9 Merath K, Chen Q, Bagante F, Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Weiss MJ, Bauer TW, Shen F, Poultsides GA, Soubrane O, Martel G, Koerkamp BG, Guglielmi A, Itaru E, Cloyd JM, Pawlik TM. A Multi-institutional International Analysis of Textbook Outcomes Among Patients Undergoing Curative-Intent Resection of Intrahepatic Cholangiocarcinoma. *JAMA Surg* 2019; **154**: e190571 [PMID: 31017645 DOI: 10.1001/jamasurg.2019.0571]
- 10 Tsilimigras DI, Sahara K, Moris D, Mehta R, Paredes AZ, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Weiss M, Bauer TW, Maithel SK, Pulitano C, Shen F, Koerkamp BG, Endo I, Pawlik TM. Assessing Textbook Outcomes Following Liver Surgery for Primary Liver Cancer Over a 12-Year Time Period at Major Hepatobiliary Centers. *Ann Surg Oncol* 2020; **27**: 3318-3327 [PMID: 32388742 DOI: 10.1245/s10434-020-08548-w]
- 11 Poelmeijer YQM, Marang-van de Mheen PJ, Wouters MWJM, Nienhuijs SW, Liem RSL. Textbook Outcome: an Ordered Composite Measure for Quality of Bariatric Surgery. *Obes Surg* 2019; **29**: 1287-1294 [PMID: 30569369 DOI: 10.1007/s11695-018-03642-1]
- 12 Nolan T, Berwick DM. All-or-none measurement raises the bar on performance. *JAMA* 2006; **295**: 1168-1170 [PMID: 16522838 DOI: 10.1001/jama.295.10.1168]
- 13 Sweigert PJ, Eguia E, Baker MS, Paredes AZ, Tsilimigras DI, Dillhoff M, Ejaz A, Cloyd J, Tsung A, Pawlik TM. Assessment of textbook oncologic outcomes following pancreaticoduodenectomy for pancreatic adenocarcinoma. *J Surg Oncol* 2020; **121**: 936-944 [PMID: 32124437 DOI: 10.1002/jso.25861]
- 14 Kalagara R, Norain A, Chang YH, Stucky CC, Wasif N. Association of Textbook Outcome and Surgical Case Volume with Long-Term Survival in Patients Undergoing Surgical Resection for Pancreatic Cancer. *J Am Coll Surg* 2022; **235**: 829-837 [PMID: 36102533 DOI: 10.1097/XCS.0000000000000407]
- 15 Sweigert PJ, Wang X, Eguia E, Baker MS, Kulshrestha S, Tsilimigras DI, Ejaz A, Pawlik TM. Does minimally invasive pancreaticoduodenectomy increase the chance of a textbook oncologic outcome? *Surgery* 2021; **170**: 880-888 [PMID: 33741181 DOI: 10.1016/j.surg.2021.02.021]
- 16 Busweiler LA, Schouwenburg MG, van Berge Henegouwen MI, Kolfshoten NE, de Jong PC, Rozema T, Wijnhoven BP, van Hillegersberg R, Wouters MW, van Sandick JW; Dutch Upper Gastrointestinal Cancer Audit (DUCA) group. Textbook outcome as a composite measure in oesophagogastric cancer surgery. *Br J Surg* 2017; **104**: 742-750 [PMID: 28240357 DOI: 10.1002/bjs.10486]
- 17 Salet N, Bremmer RH, Verhagen MAMT, Ekkelenkamp VE, Hansen BE, de Jonge PJF, de Man RA. Is Textbook Outcome a valuable composite measure for short-term outcomes of gastrointestinal treatments in the Netherlands using hospital information system data? A retrospective cohort study. *BMJ Open* 2018; **8**: e019405 [PMID: 29496668 DOI: 10.1136/bmjopen-2017-019405]
- 18 Donabedian A. Evaluating the quality of medical care. 1966. *Milbank Q* 2005; **83**: 691-729 [PMID: 16279964 DOI: 10.1111/j.1468-0009.2005.00397.x]
- 19 Amin MB, Greene FL, Edge SB, Compton CC, Gershengwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. *CA Cancer J Clin* 2017; **67**: 93-99 [PMID: 28094848 DOI: 10.3322/caac.21388]
- 20 Sweigert PJ, Eguia E, Baker MS, Link CM, Hyer JM, Paredes AZ, Tsilimigras DI, Husain S, Pawlik TM. Assessment of Cancer Center Variation in Textbook Oncologic Outcomes Following Colectomy for Adenocarcinoma. *J Gastrointest Surg* 2021; **25**: 775-785 [PMID: 32779080 DOI: 10.1007/s11605-020-04767-4]
- 21 Clark RE. The development of The Society of Thoracic Surgeons voluntary national database system: genesis, issues, growth, and status. *Best Pract Benchmarking Healthc* 1996; **1**: 62-69 [PMID: 9192577]
- 22 Dimick JB, Welch HG, Birkmeyer JD. Surgical mortality as an indicator of hospital quality: the problem with small sample size. *JAMA* 2004; **292**: 847-851 [PMID: 15315999 DOI: 10.1001/jama.292.7.847]
- 23 Lawson EH, Zingmond DS, Stey AM, Hall BL, Ko CY. Measuring risk-adjusted value using Medicare and ACS-NSQIP: is high-quality, low-cost surgical care achievable everywhere? *Ann Surg* 2014; **260**: 668-77; discussion 677 [PMID: 25203884 DOI: 10.1097/SLA.0000000000000931]
- 24 Siracuse JJ, Schermerhorn ML, Meltzer AJ, Eslami MH, Kalish JA, Rybin D, Doros G, Farber A; Vascular Study Group of New England. Comparison of outcomes after endovascular and open repair of abdominal aortic aneurysms in low-risk patients. *Br J Surg* 2016; **103**: 989-994 [PMID: 27138354 DOI: 10.1002/bjs.10139]
- 25 Prinssen M, Verhoeven EL, Buth J, Cuypers PW, van Sambeek MR, Balm R, Buskens E, Grobbee DE, Blankensteijn JD; Dutch Randomized Endovascular Aneurysm Management (DREAM) Trial Group. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. *N Engl J Med* 2004; **351**: 1607-1618 [PMID: 15483279 DOI: 10.1056/NEJMoa042002]
- 26 Shahian DM, Edwards FH, Ferraris VA, Haan CK, Rich JB, Normand SL, DeLong ER, O'Brien SM, Shewan CM, Dokholyan RS, Peterson ED; Society of Thoracic Surgeons Quality Measurement Task Force. Quality measurement in adult cardiac surgery: part 1--Conceptual framework and measure selection. *Ann Thorac Surg* 2007; **83**: S3-12 [PMID: 17383407 DOI: 10.1016/j.athoracsur.2007.01.053]
- 27 Li M, Zhang W, Jiang L, Yang J, Yan L. Fast track for open hepatectomy: A systemic review and meta-analysis. *Int J Surg* 2016; **36**: 81-89 [PMID: 27773599 DOI: 10.1016/j.ijsu.2016.10.019]
- 28 Chen Q, Olsen G, Bagante F, Merath K, Idrees JJ, Akgul O, Cloyd J, Dillhoff M, White S, Pawlik TM. Procedure-Specific Volume and Nurse-to-Patient Ratio: Implications for Failure to Rescue Patients Following Liver Surgery. *World J Surg* 2019; **43**: 910-919 [PMID: 30465087 DOI: 10.1007/s00268-018-4859-4]
- 29 Nathan H, Yin H, Wong SL. Postoperative Complications and Long-Term Survival After Complex Cancer Resection. *Ann Surg Oncol* 2017; **24**: 638-644 [PMID: 27619939 DOI: 10.1245/s10434-016-5569-5]
- 30 Kulshrestha S, Bunn C, Patel PM, Sweigert PJ, Eguia E, Pawlik TM, Baker MS. Textbook oncologic outcome is associated with increased overall survival after esophagectomy. *Surgery* 2020; **168**: 953-961 [PMID: 32675034 DOI: 10.1016/j.surg.2020.05.038]
- 31 Aquina CT, Hamad A, Becerra AZ, Cloyd JM, Tsung A, Pawlik TM, Ejaz A. Is Textbook Oncologic Outcome a Valid Hospital-Quality Metric after High-Risk Surgical Oncology Procedures? *Ann Surg Oncol* 2021; **28**: 8028-8045 [PMID: 34392460 DOI: 10.1245/s10434-021-10478-0]
- 32 Heidsma CM, Hyer M, Tsilimigras DI, Rocha F, Abbott DE, Fields R, Smith PM, Poultsides GA, Cho C, Maithel SK, Pawlik TM; Other Members of the US Neuroendocrine Tumor Study Group. Incidence and impact of Textbook Outcome among patients undergoing resection of

- pancreatic neuroendocrine tumors: Results of the US Neuroendocrine Tumor Study Group. *J Surg Oncol* 2020; **121**: 1201-1208 [PMID: 32185804 DOI: 10.1002/jso.25900]
- 33 **van Roessel S**, Mackay TM, van Dieren S, van der Schelling GP, Nieuwenhuijs VB, Bosscha K, van der Harst E, van Dam RM, Liem MSL, Festen S, Stommel MWJ, Roos D, Wit F, Molenaar IQ, de Meijer VE, Kazemier G, de Hingh IHJT, van Santvoort HC, Bonsing BA, Busch OR, Groot Koerkamp B, Besselink MG; Dutch Pancreatic Cancer Group. Textbook Outcome: Nationwide Analysis of a Novel Quality Measure in Pancreatic Surgery. *Ann Surg* 2020; **271**: 155-162 [PMID: 31274651 DOI: 10.1097/SLA.0000000000003451]
 - 34 **Wu L**, Tsilimigras DI, Paredes AZ, Mehta R, Hyer JM, Merath K, Sahara K, Bagante F, Beal EW, Shen F, Pawlik TM. Trends in the Incidence, Treatment and Outcomes of Patients with Intrahepatic Cholangiocarcinoma in the USA: Facility Type is Associated with Margin Status, Use of Lymphadenectomy and Overall Survival. *World J Surg* 2019; **43**: 1777-1787 [PMID: 30820734 DOI: 10.1007/s00268-019-04966-4]
 - 35 **Idrees JJ**, Merath K, Gani F, Bagante F, Mehta R, Beal E, Cloyd JM, Pawlik TM. Trends in centralization of surgical care and compliance with National Cancer Center Network guidelines for resected cholangiocarcinoma. *HPB (Oxford)* 2019; **21**: 981-989 [PMID: 30591307 DOI: 10.1016/j.hpb.2018.11.013]
 - 36 **Merath K**, Chen Q, Bagante F, Beal E, Akgul O, Dillhoff M, Cloyd JM, Pawlik TM. Textbook Outcomes Among Medicare Patients Undergoing Hepatopancreatic Surgery. *Ann Surg* 2020; **271**: 1116-1123 [PMID: 30499800 DOI: 10.1097/SLA.0000000000003105]
 - 37 **Hyer JM**, Beane JD, Spolverato G, Tsilimigras DI, Diaz A, Paro A, Dalmacy D, Pawlik TM. Trends in Textbook Outcomes over Time: Are Optimal Outcomes Following Complex Gastrointestinal Surgery for Cancer Increasing? *J Gastrointest Surg* 2022; **26**: 50-59 [PMID: 34506022 DOI: 10.1007/s11605-021-05129-4]
 - 38 **Azap RA**, Paredes AZ, Diaz A, Hyer JM, Pawlik TM. The association of neighborhood social vulnerability with surgical textbook outcomes among patients undergoing hepatopancreatic surgery. *Surgery* 2020; **168**: 868-875 [PMID: 32800602 DOI: 10.1016/j.surg.2020.06.032]
 - 39 **Mehta R**, Paredes AZ, Tsilimigras DI, Moro A, Sahara K, Farooq A, Dillhoff M, Cloyd JM, Tsung A, Ejaz A, Pawlik TM. Influence of hospital teaching status on the chance to achieve a textbook outcome after hepatopancreatic surgery for cancer among Medicare beneficiaries. *Surgery* 2020; **168**: 92-100 [PMID: 32303348 DOI: 10.1016/j.surg.2020.02.024]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

